2014
DOI: 10.1136/ejhpharm-2013-000436.49
|View full text |Cite
|
Sign up to set email alerts
|

CP-050 Adherence to protein tyrosine kinase inhibitors treatment in Chronic Myeloid Leukaemia and Gastrointestinal Stromal Tumours

Abstract: Background Tyrosine Kinase Inhibitors (TKI) are the standard treatment for Philadelphia chromosome positive chronic myeloid leukaemia (Ph + CML). Imatinib is also indicated for Kit- (CD117) positive metastatic malignant gastrointestinal stromal tumours. The high rates of survival obtained in recent years have turned these diseases into chronic conditions. Thus, adherence to treatment is hugely important. Many studies have shown that low adherence to treatment with imatinib (<85–90%) is related to a loss of cyt… Show more

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles